JosephRosenthalMD

Pediatric Hematology & Oncology • Duarte, CA

Director, Pediatric Hematology/Oncology

Join to view full profile

Dr. Rosenthal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rosenthal's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-408-3911

Education & Training

University of California (Irvine)/Children's Hospital of Orange CountyFellowship, Pediatric Hematology/Oncology, 1993 - 1996
University of ColoradoFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Tel Aviv University SacklerClass of 1983

Certifications & Licensure

CA State Medical License 1956 - 2025
NJ State Medical License 2024 - 2025
WY State Medical License 1990 - 1994
CO State Medical License 1991 - 1993
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies Start of enrollment: 2006 Jul 31
Active, not recruiting
Phase 1, Phase 2
A Blood Stem Cell Transplant for Sickle Cell Disease Start of enrollment: 2019 Jan 04
Active, not recruiting
Phase 1
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease Start of enrollment: 2018 Sep 19
Recruiting
Phase 1
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Start of enrollment: 2022 Jul 13
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Late morbidity and mortality after autologous blood or marrow transplantation for lymphoma in children, adolescents and young adults-a BMTSS report.
Anna Sällfors Holmqvist, Qingrui Meng, Chen Dai, Lindsey Hageman, Wendy Landier
Leukemia. 2024-03-01
1 citations
Severe, life-threatening, and fatal chronic health conditions after allogeneic blood or marrow transplantation in childhood.
Anna Sällfors Holmqvist, Yanjun Chen, Lindsey Hageman, Wendy Landier, Jessica Wu
Cancer. 2023-02-15
3 citations
Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early F...
Colton Ladbury, Saro Armenian, Alysia Bosworth, Tianhui He, F Lennie Wong
Transplantation and Cellular Therapy. 2022-12-01

Abstracts/Posters

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Joseph Rosenthal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Life-Changing Transplant Gives Sickle Cell Patient a Second ChanceOctober 3rd, 2018
$City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia$
City of Hope Certified to Provide First FDA-Approved CAR T Cell Therapy for Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic LeukemiaApril 13th, 2018
Promising Sickle Cell Research Gets Nearly $6MM Boost from CIRMMarch 22nd, 2018
Join now to see all

Professional Memberships

Hematology Research Laboratory, Soroka Medical Center
Member

Other Languages

Hebrew